What is the LKM Test in Liver Disease?
The LKM (liver-kidney microsomal) test detects autoantibodies that target cytochrome P450 enzymes, primarily CYP2D6, and serves as the diagnostic hallmark for autoimmune hepatitis type 2 (AIH-2), though it can also appear in hepatitis C infection and certain drug-induced liver injuries.
Test Methodology and Detection
The LKM antibody test is performed using indirect immunofluorescence (IIF) on tissue sections (rat liver and kidney), which remains the reference standard 1. The characteristic pattern shows:
- Cytoplasmic staining of hepatocytes throughout the liver lobule
- Staining of proximal renal tubules in kidney tissue
- This dual liver-kidney staining pattern gives the antibody its name
Commercial ELISA formats are now available using recombinant CYP2D6 antigen, which can be accurate for AIH-2 detection 1, though external validation is still needed and agreement with reference methods varies 2.
Clinical Significance of Positive Results
Primary Association: Autoimmune Hepatitis Type 2
A positive anti-LKM-1 result is the serological marker defining AIH-2 1. Key features:
- Highly specific for AIH-2 in adults with chronic active hepatitis 3
- Typically occurs in younger patients (children and young adults)
- Requires prompt initiation of immunosuppressive treatment 1
- In U.S. referral centers, anti-LKM-1 is relatively infrequent in adults with chronic hepatitis 3
Secondary Associations
Hepatitis C Virus (HCV) infection: Anti-LKM-1 appears in up to 6% of HCV patients 4, 5. These patients:
- Have chronic liver disease with anti-HCV positivity
- May respond favorably to interferon therapy 5
- The antibody recognizes the same CYP2D6 target as in AIH-2
Drug-induced liver injury (DILI): Recent evidence shows LKM positivity can occur in drug-induced autoimmune-like hepatitis 6:
- Metamizole (dipyrone) is strongly associated, accounting for 52% of LKM-positive DILI cases
- Can cause severe outcomes requiring liver transplantation
- Other drugs historically associated include tienilic acid (anti-LKM-2) and halothane
Subtypes and Variants
Anti-LKM-1 (most clinically relevant):
- Targets cytochrome P450 2D6 (CYP2D6)
- Diagnostic for AIH-2 and occasionally seen in HCV 1
Anti-LKM-2: Directed against CYP2C9, associated with tienilic acid-induced hepatitis (drug no longer marketed) 1
Anti-LKM-3: Targets UDP glucuronosyltransferases, occurs in hepatitis D and rarely in AIH-2 1
Critical Diagnostic Pitfalls
Confusion with anti-mitochondrial antibodies (AMA): LKM immunofluorescence patterns can be misinterpreted as AMA positivity 1, 3. This confusion can be resolved by:
- Using immunoassays with purified/recombinant antigens 1
- Recognizing that AMA and LKM have different density gradient localizations (1.28 g/ml vs 1.20 g/ml) 7
False positives in commercial ELISAs: Recent data shows variable agreement between commercial ELISAs and reference methods 2. Patients with high suspicion of autoimmune liver disease should be referred to reference laboratories using gold standard IIF methods if initial ELISA screening is performed 2.
Polyreactive IgG interference: There is a trend toward higher polyreactive IgG levels in false-positive commercial ELISA results 2.
Practical Testing Recommendations
When ordering LKM testing:
- Request indirect immunofluorescence as the reference method for definitive diagnosis 1
- If using commercial ELISA, confirm positive results with IIF 2
- Test in conjunction with other autoimmune markers (ANA, SMA, anti-LC1, anti-SLA/LP) for complete AIH evaluation 1, 8
- Consider drug history, particularly metamizole exposure, in LKM-positive cases 6
- Check HCV serology, as this can guide treatment decisions (interferon vs. steroids) 5